<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955848</url>
  </required_header>
  <id_info>
    <org_study_id>35/2017/O/Sper</org_study_id>
    <nct_id>NCT03955848</nct_id>
  </id_info>
  <brief_title>INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS</brief_title>
  <acronym>NKAML</acronym>
  <official_title>INFUSION OF ALLOREACTIVE NK CELLS AS CONSOLIDATION STRATEGY FOR ADULT ACUTE MYELOID LEUKEMIA PATIENTS: A MULTICENTER CLINICAL STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Myeloid Leukemia (AML) patients who had achieved Complete Remission (CR) after
      (re)induction/consolidation chemotherapy will receive the infusion of alloreactive NK cells.
      Adult AML patients in morphologic, but not cytogenetic and/or molecular CR and AML patients
      in morphologic plus cytogenetic and/or molecular CR, not eligible for Stem Cell
      Transplantation (SCT), will be included. Using a genetic randomization through a 'donor' vs
      'no donor' approach, patients will undergo NK cell infusion (ARM 1) or followed-up without
      treatment (ARM 2). Donor alloreactive NK cell repertoire will be evaluated in order to
      determine the functional cell dose to be used for NK cell collection. NK cells will be
      selected from a steady-state large volume leukapheresis product from a suitable KIR-ligand
      incompatible donor. NK cell purification will be performed if the donor leukapheresis product
      contains at least 10x106 NK cells/Kg, otherwise the final decision for proceeding to NK
      purification will be made by the PI after careful evaluation of the number of alloreactive If
      the minimum collected cell dose of 2x105 total alloreactive NK cells/kg is not reached after
      a single leukapheresis, donors could undergo a second PB collection within 30 days from the
      first one. Patients will receive immunosuppressive chemotherapy, fludarabine (Flu) 25 mg/mq/
      from day -7 to -3 and cyclophosphamide (Cy) 4 g/mq on day -2 (Flu/Cy). Immunosuppressive
      chemotherapy is not part of the procedures under study and it is used to favor NK cell
      engraftment. Two days after Cy administration, patients will be infused intravenously with a
      single dose of cryopreserved NK cells (day 0), which will be followed by subcutaneous
      administration of Interleuki (IL)-2 (10 x 106 IU/day, 3 times weekly) for 2 weeks (6 doses
      total). IL-2 administration is not part of the procedures under study and it is used to favor
      early in vivo expansion of infused NK cells. Peripheral blood samples will be collected for
      molecular assessment of microchimerism and tracking of NK cells for 30 days, immunophenotype
      studies, alloreactive NK cells cloning and functional assays. Bone marrow aspirate will be
      performed once a week until hematological recovery. Enrolled patients (ARM1 and 2) will be
      followed up for at least 12 months after NK cell infusion. RFS is defined as the time from
      patient enrollment to disease relapse.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Anticipated">May 11, 2022</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>36 months</time_frame>
    <description>relapse-free survival (RFS) of AML patients, not eligible for SCT, who undergo alloreactive NK cell infusion after the achievement of CR with induction/consolidation chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>overall survival (RFS) of AML patients, not eligible for SCT, who undergo alloreactive NK cell infusion after the achievement of CR with induction/consolidation chemotherapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NK cell infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow up without treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alloreactive NK cell infusion</intervention_name>
    <description>Alloreactive NK cell infusion</description>
    <arm_group_label>ARM 1</arm_group_label>
    <other_name>Alloreactive NK cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

               -  AML patients in morphologic, but not cytogenetic or molecular CR

               -  AML patients in morphologic plus cytogenetic or molecular CR

          -  Performance Status ≥ 70% (Karnofsky score) or ≤ 2 (WHO)

          -  Age ≥ 18 years

          -  Adequate renal (serum creatinine &lt; 2 mg/dl), pulmonary (Sat O2 ≥ 96%) and hepatic
             function.

          -  Left Ventricular Ejection Fraction (LVEF) of ≥ 50% as determined by - Echocardiogram

        Exclusion Criteria:

          -  Eligibility to SCT

          -  Low-risk AML patients in molecular CR

          -  HIV positivity.

          -  Hepatiti C Virus positivity (serology and viremia)

          -  Pregnant or nursing females

          -  Current uncontrolled infection

          -  Signs or symptoms of fluid retention (e.g. pleural effusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Curti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto di Ematologia Seràgnoli, Ospedale S.Orsola-Malpighi, Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Curti</last_name>
    <phone>+390512144074</phone>
    <email>antonio.curti2@unibo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antonio Curti</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Curti</last_name>
      <phone>+390512144074</phone>
      <email>antonio.curti2@unibo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Antonio Curti</investigator_full_name>
    <investigator_title>Medical Doctor, Hematologist</investigator_title>
  </responsible_party>
  <keyword>AML in Remission</keyword>
  <keyword>NK cells</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

